These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 34160251)
1. Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. Li Y; Bai H; Sanders-Buell E; Dussupt V; Townsley S; Donofrio G; Bose M; O'Sullivan AM; Kibuuka H; Maganga L; Nitayaphan S; Kosgei J; Pitisuttithum P; Rerks-Ngarm S; Eller LA; Michael NL; Robb ML; Ake J; Vasan S; Tovanabutra S; Krebs SJ; Rolland M J Virol; 2021 Aug; 95(17):e0079721. PubMed ID: 34160251 [TBL] [Abstract][Full Text] [Related]
2. Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth. Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Hunter E; Derdeyn CA PLoS Pathog; 2016 Nov; 12(11):e1005989. PubMed ID: 27851829 [TBL] [Abstract][Full Text] [Related]
3. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996 [TBL] [Abstract][Full Text] [Related]
4. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. Schorcht A; Cottrell CA; Pugach P; Ringe RP; Han AX; Allen JD; van den Kerkhof TLGM; Seabright GE; Schermer EE; Ketas TJ; Burger JA; van Schooten J; LaBranche CC; Ozorowski G; de Val N; Bader DLV; Schuitemaker H; Russell CA; Montefiori DC; van Gils MJ; Crispin M; Klasse PJ; Ward AB; Moore JP; Sanders RW J Virol; 2022 Jan; 96(1):e0155221. PubMed ID: 34669426 [TBL] [Abstract][Full Text] [Related]
6. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop. Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999 [TBL] [Abstract][Full Text] [Related]
7. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency. Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728 [TBL] [Abstract][Full Text] [Related]
8. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs. Li H; Zony C; Chen P; Chen BK J Virol; 2017 May; 91(9):. PubMed ID: 28148796 [TBL] [Abstract][Full Text] [Related]
9. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies. Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M mBio; 2020 Jan; 11(1):. PubMed ID: 31937648 [TBL] [Abstract][Full Text] [Related]